References
- Arcamone F., Bernard L., Giardino P., Patelli B., DiMarco A., Casazza A. M., Pratesi P. Synthesis and anti-tumor activity of 4-demethoxydaunorubicin, 4-deme-thoxy 7.9 diepidaunorubicin and their B anomers. Cancer Treat. Rep. 1976; 60: 829–834
- Giuliani F. C., Spreafico F., Casazza A. M. Preclin-ical studies on new anthracyclines: Antitumor toxicologic and pharmacologic properties. Excerpt Medica, H. H. Hansen. Anthracyclines and Cancer Therapy, Amsterdam 1983; 193–207
- Bonfante V., Ferrari F., Villani L., Bonadonna G. Phase I study of 4-demethoxy-daunorubicin. Invest. New Drugs 1983; 1: 161–168
- Kaplan S., Sessa C., Willems Y., Pacciarini M. A., Ta-massia V., Cavalli F. Phase I trial of 4-demethoxydau-norubicin (idarubicin) with single oral doses. Invest. New Drugs 1984; 2: 281–286
- Coonley C. J., Warrell R. P., Jr., Straus D. J., Young C. W. Clinical evaluation of 4-demethoxydaunorub-icin in patients with advanced malignant lymphoma. Cancer Treat. Rep. 1983; 67: 949–950
- Lopez M., DiLauro L., Papaldo P. Oral idarubicin in non-Hodgkin's lymphoma. Invest. New Drugs 1986; 4: 263–267
- Case D. C., Jr., Hayes D. M., Gerber M., Gams R., Ervin T. J., Dorsk B. M. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Cancer Res. 1990; 50: 6833–6835
- Krueger G., Medina J., Klein H., Konrads A., Zach J., Rister M., Janik G., Evers K., Hirano T., Kitamura H., Bedoya V. A new working formulation of non-Hodgkin's lymphomas. Cancer 1983; 52: 833–840
- Rappaport H. Tumours of the hematopoietic system (pages 66–76). In: Atlas of Tumour Pathology. Armed Forces Institute of Pathology, Washington, D.C. 1966
- Alexander J., Dainiak N., Berger H., Goldman L., Johnstone D., Reduto L., Duffy T., Schwartz P., God-dacalt A., Zaret B. Serial assessment of doxorubicin cardiomyopathy with quantitative radionuclide angiography. N. Engl. J. Med. 1979; 300: 278–283